Malic enzyme 2 as a potential therapeutic drug target for cancer

Basit Öğe Kaydı
dc.contributor.authorSarfraz I.
dc.contributor.authorRasul A.
dc.contributor.authorHussain G.
dc.contributor.authorHussain S.M.
dc.contributor.authorAhmad M.
dc.contributor.authorNageen B.
dc.contributor.authorAli M.
dc.date.accessioned2019-08-01T13:38:39Z
dc.date.available2019-08-01T13:38:39Z
dc.date.issued2018
dc.departmentNiğde ÖHÜ
dc.description.abstractReprogrammed metabolic profile is a biochemical fingerprint of cancerous cells, which represents one of the “hallmarks of cancer.” The aberrant expression pattern of enzymatic machineries orchestrates metabolic activities into a platform that ultimately promotes cellular growth, survival, and proliferation. The NADP(+)-dependent mitochondrial malic enzyme 2 (ME2) has been widely appreciated due to its function as a provider of pyruvate and reducing power to the cell for biosynthesis of fatty acids and nucleotides along with maintenance of redox balance. Multiple lines of evidences have indicated that ME2 is a bonafide therapeutic target and novel biomarker which plays critical role during tumorigenesis. The objective of this review is to provide an update on the cancer-specific role of ME2 in order to explore its potential for therapeutic opportunities. Furthermore, we have discussed the potential of genetic and pharmacological inhibitors of ME2 in the light of previous research work for therapeutic advancements in cancer treatment. It is contemplated that additional investigations should focus on the use of ME2 inhibitors in combinational therapies as rational combinations of metabolic inhibitors and chemotherapy may have the ability to cure cancer. © 2018 IUBMB Life, 70(11):1076–1083, 2018. © 2018 International Union of Biochemistry and Molecular Biology
dc.description.sponsorshipThis study was supported by the research grant The Nagai Foundation Tokyo, Japan (NFT-R-2018) and NRPU Research Grant (8381/Punjab/NRPU/R&D/HEC/2017). Authors would also like to thank Higher Education Commission (HEC), Pakistan for providing access to related papers from various journals.
dc.identifier.doi10.1002/iub.1930
dc.identifier.endpage1083
dc.identifier.issn1521-6543
dc.identifier.issue11
dc.identifier.pmid30160039
dc.identifier.scopus2-s2.0-85052797763
dc.identifier.scopusqualityQ1
dc.identifier.startpage1076
dc.identifier.urihttps://dx.doi.org/10.1002/iub.1930
dc.identifier.urihttps://hdl.handle.net/11480/1591
dc.identifier.volume70
dc.identifier.wosWOS:000447405400003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[0-Belirlenecek]
dc.language.isoen
dc.publisherBlackwell Publishing Ltd
dc.relation.ispartofIUBMB Life
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectcancer
dc.subjectdrug target
dc.subjectmalic enzyme 2
dc.subjecttumor metabolism
dc.titleMalic enzyme 2 as a potential therapeutic drug target for cancer
dc.typeReview Article

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu